Biofluid Detection of Pathological α -Synuclein in the Prodromal Phase of Synucleinopathies
Journal of Parkinson’s Disease · 2024
DOI: 10.3233/jpd-230429 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Parkinson’s Disease, 2024. Verfasst von Annika Kluge und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospital Schleswig-Holstein, Campus Kiel and Kiel University, Kiel, Germany. Hauptthemen laut MEDLINE: alpha-Synuclein, Prodromal Symptoms, Synucleinopathies. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Synucleinopathies are disorders characterized by the aggregation and deposition of pathological α-synuclein conformers. The underlying neurodegenerative processes begin years or decades before the onset of cardinal motor symptoms. This prodromal phase may manifest with various signs or symptoms. However, there are no current standardized laboratory tests to ascertain the progression and conversion of prodromal conditions such as mild cognitive impairment, isolated REM sleep behavior disorder or pure autonomic failure. The aim of this systematic review was to evaluate the diagnostic possibilities using human biofluids as source material to detect pathological α-synuclein in the prodromal phase of synucleinopathies. Our review identified eight eligible studies, that investigated pathological α-synuclein conformers using cerebrospinal fluid from patients with prodromal signs of synulceinopathies to differentiate this patient group from non-synucleinopathies, while only one study investigated this aspect using blood as medium. While previous studies clearly demonstrated a high diagnostic performance of α-synuclein seed amplification assays for differentiating synucleinopathies with Lewy bodies from healthy controls, only few analyses were performed focussing on individuals with prodromal disease. Nevertheless, results for the early detection of α-synuclein seeds using α-synuclein seed amplification assays were promising and may be of particular relevance for future clinical trials and clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University Hospital Schleswig-Holstein, Campus Kiel and Kiel University, Kiel, Germany.
- Sleep Unit, Neurology Service, Hospital Clínic Barcelona, Barcelona University, IDIBAPS, CIBERNED, Barcelona, Spain.
Zitieren
APA
Kluge, A., & Iranzo, A. (2024). Biofluid Detection of Pathological α -Synuclein in the Prodromal Phase of Synucleinopathies. Journal of Parkinson’s Disease. https://doi.org/10.3233/jpd-230429
Vancouver
Kluge A, Iranzo A. Biofluid Detection of Pathological α -Synuclein in the Prodromal Phase of Synucleinopathies. Journal of Parkinson’s Disease. 2024. doi:10.3233/jpd-230429
BibTeX
@article{Kluge2024,
author = {Kluge, Annika and Iranzo, Alex},
title = {Biofluid Detection of Pathological α -Synuclein in the Prodromal Phase of Synucleinopathies},
journal = {Journal of Parkinson’s Disease},
year = {2024},
doi = {10.3233/jpd-230429}
}
EUVIMED